Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study.


Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
08 2021
Historique:
accepted: 17 02 2021
pubmed: 3 3 2021
medline: 25 2 2023
entrez: 2 3 2021
Statut: ppublish

Résumé

To estimate the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the general population in southern Sweden. The study sample comprised 653 patients with GCA along with 10 age-, sex-, and residency area-matched reference subjects per patient. Data on public and private healthcare consultations and hospitalizations were extracted from the Skåne Healthcare Register. We assessed trajectories of primary and specialist healthcare visits, as well as hospital admissions and inpatient days from 3 years before through 5 years after the date of GCA diagnosis for patients and matched references. HRU was analyzed using generalized estimating equations adjusted for sex, age at the index year, calendar year of diagnosis, education, income, marital status, place of birth, and Charlson Comorbidity Index. Inverse probability weighting was used to account for dropout during study. Patients with GCA had higher rates of healthcare visits than the references from the year before GCA diagnosis and up to 4 years after diagnosis, with the largest relative (rate ratio 1.85, 95% CI 1.68-2.05) and absolute (mean difference 10.2, 95% CI 8.1-12.3 visits per person) differences in the year of diagnosis. Similar trajectories were observed for primary and specialist healthcare visits. For hospital admissions and inpatient days, the differences disappeared 1 year after diagnosis date. Patients with GCA utilized healthcare services at a significantly higher rate than the reference population. The increased utilization among Swedish patients with GCA was evident 1 year before and prolonged up to 4 years after diagnosis date.

Identifiants

pubmed: 33649063
pii: jrheum.201131
doi: 10.3899/jrheum.201131
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1307-1313

Informations de copyright

© 2021 The Journal of Rheumatology.

Auteurs

Aladdin J Mohammad (AJ)

A.J. Mohammad, MD, MPH, PhD, Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden, and Department of Medicine, University of Cambridge, Cambridge, UK; aladdin.mohammad@med.lu.se.

Aleksandra Turkiewicz (A)

A. Turkiewicz, PhD, M. Englund, MD, PhD, Clinical Epidemiology Unit, Lund University, Lund, Sweden.

Pavlos Stamatis (P)

P. Stamatis, MD, Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden.

Carl Turesson (C)

C. Turesson, MD, PhD, Department of Clinical Sciences, Rheumatology, Lund University, Malmö, Sweden.

Martin Englund (M)

A. Turkiewicz, PhD, M. Englund, MD, PhD, Clinical Epidemiology Unit, Lund University, Lund, Sweden.

Ali Kiadaliri (A)

A. Kiadaliri, PhD, Clinical Epidemiology Unit, and Centre for Economic Demography, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH